Env-Specific B Cell Repertoire Responses to NFL Trimer vaccines
对 NFL 三聚体疫苗的环境特异性 B 细胞库反应
基本信息
- 批准号:9111304
- 负责人:
- 金额:$ 55.32万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:AddressAffinity ChromatographyAnimal ModelAnimalsAntibodiesAntibody ResponseAntigensB cell repertoireB-LymphocytesBindingBloodCell CountCell LineageCell SeparationDataDevelopmentEpitopesEvaluationEvolutionGene Expression ProfileGene Expression ProfilingGenesHIVHIV-1HumanImmune responseImmunizationInbred MouseIndividualInfectionLengthLightLinkMacacaMacaca mulattaMessenger RNAMicrofluidicsModelingMonoclonal AntibodiesMusOryctolagus cuniculusOutcomePathway interactionsPatternPhasePropertyRNAReportingResearch PersonnelSeriesSerumSorting - Cell MovementStructureSystemTechnologyVaccinationVaccine DesignVaccinesVesicular stomatitis Indiana virusVirusVirus-like particlebasedeep sequencingdesignenv Glycoproteinshumanized mousein vivolongitudinal analysismouse modelneutralizing antibodyneutralizing monoclonal antibodiesnew technologynext generation sequencingnonhuman primatenovelprogramsresponsesingle cell analysisvaccine candidatevaccine deliveryvaccine developmentvaccine trialvector
项目摘要
Project Summary
Broadly neutralizing antibodies (bnAbs) recognize conserved epitopes on the envelope glycoprotein (Env) of
the human immunodeficiency virus type-1 (HIV-1). Atomic structures of the BG505 SOSIP.664 gp140 trimer
have provided a rational framework for Env-based HIV-1 vaccine design. The Wyatt group recently developed
a cleavage-independent, native flexibly linked (NFL) trimer, which offers a promising alternative for Env-based
vaccine design. Vaccine delivery is a critical issue yet to be addressed in developing well-folded trimers toward
vaccine products. In a recent review, Schiller et al. promoted a virus-like particle (VLP) approach for HIV-1
vaccine delivery. Other delivery systems include mRNA and virus vectors. For the NFL trimer, it remains
unclear which delivery system will produce the most robust immune response to enable protection against HIV-
1 infection. We hypothesize that a quantitative readout of B-cell response will facilitate rational evaluation of
vaccine candidates since a robust cross-neutralizing antibody response is expected for an effective HIV-1
vaccine. Next-generation sequencing (NGS) has been widely used to study the diversity and maturation of
bnAbs. We have developed a series of novel NGS technologies for the analysis of dynamic B-cell responses in
natural infection, animal immunization, and human vaccine trials. In Project 3 of this HIVRAD application, we
will investigate the Env-specific B-cell response to four vaccines based on the NFL trimer and different delivery
systems in various animal models – inbred mice, VelocImmune mice, rabbits and non-human primates (NHPs).
In Aim 1, we will deep sequence the B-cell response of inbred mice, VelocImmune mice, and rabbits immunized
with four vaccines. We will characterize the basic repertoire properties such as germline gene usage, degree of
SHM, and CDR3 length and identify distinctive repertoire patterns associated with each vaccine. For each
animal model, we will compare the B-cell responses to four vaccines. We will compare the B-cell responses in
hu-mice and human vaccine trials. In Aim 2, we will deep sequence the B-cell response in NHPs immunized
with four vaccines. Similarly, we will characterize the basic repertoire properties and identify distinctive patterns
associated with four vaccines in the NHP model. We will compare the B-cell responses to four vaccines and
compare the B-cell responses in NHPs and human vaccine trials. In Aim 3, we will study the developmental
pathways of Env-specific B-cell lineages elicited by four vaccines. We will trace the lineages of monoclonal
antibodies (mAbs) identified by single B-cell sorting (Project 2, Wyatt) and microfluidics-based single-cell
analysis (Project 3, Zhu) in NGS repertoires. We will investigate whether the vaccine-elicited neutralizing mAbs
resemble known bnAbs and their developmental pathways. Project 3, together with Project 1 (RNA and VSV
vector), Project 2 (NFL trimer, VLP, and serum Ab analysis), and two Cores on in-vivo study and gene
expression profiling, will constitute a comprehensive HIVRAD program towards an effective HIV-1 vaccine.
项目摘要
广泛中和抗体(bnAb)识别大肠杆菌的包膜糖蛋白(Env)上的保守表位。
人类免疫缺陷病毒1型(HIV-1)。BG 505 SOSIP.664 gp 140三聚体的原子结构
为基于Env的HIV-1疫苗设计提供了合理的框架。怀亚特集团最近开发了
不依赖于切割的天然柔性连接(NFL)三聚体,其为基于Env的
疫苗设计疫苗递送是在开发良好折叠的三聚体中尚未解决的关键问题,
疫苗产品。在最近的一篇综述中,Schiller等人提出了一种针对HIV-1的病毒样颗粒(VLP)方法
疫苗运送其他递送系统包括mRNA和病毒载体。对于NFL三聚体,它仍然是
目前尚不清楚哪种输送系统将产生最强烈的免疫反应,以保护人体免受艾滋病毒感染-
1例感染。我们假设,B细胞反应的定量读数将有助于合理评估
候选疫苗,因为对于有效的HIV-1疫苗,
疫苗下一代测序(NGS)已被广泛用于研究基因组的多样性和成熟度。
bnAbs。我们已经开发了一系列新的NGS技术,用于分析动态B细胞反应,
自然感染、动物免疫和人类疫苗试验。在这个HIVRAD应用程序的项目3中,我们
将研究Env特异性B细胞对基于NFL三聚体和不同递送的四种疫苗的反应
系统在各种动物模型-近交系小鼠,VelocImmune小鼠,兔和非人灵长类动物(NHP)。
在目标1中,我们将对近交系小鼠、VelocImmune小鼠和免疫兔的B细胞反应进行深度测序
四种疫苗我们将描述基本的剧目性质,如种系基因的使用,程度,
SHM和CDR 3长度,并鉴定与每种疫苗相关的独特库模式。为每个
在动物模型中,我们将比较B细胞对四种疫苗的反应。我们将比较B细胞反应,
人类-小鼠和人类疫苗试验。在目标2中,我们将对免疫的NHP中的B细胞应答进行深度测序,
四种疫苗同样,我们将描述基本的剧目属性,并确定独特的模式
与NHP模型中的四种疫苗相关。我们将比较B细胞对四种疫苗的反应,
比较NHP和人类疫苗试验中的B细胞反应。在目标3中,我们将研究发展
Env特异性B细胞谱系的途径。我们将追踪单克隆抗体的谱系
通过单B细胞分选(项目2,Wyatt)和基于微流体的单细胞
分析(项目3,朱)在NGS剧目。我们将研究疫苗是否引发中和mAb
类似于已知的bnAb及其发育途径。项目3,连同项目1(RNA和VSV
载体),项目2(NFL三聚体,VLP和血清Ab分析),以及两个核心的体内研究和基因
表达谱分析,将构成一个全面的HIVRAD计划,以有效的HIV-1疫苗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jiang Zhu其他文献
Jiang Zhu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jiang Zhu', 18)}}的其他基金
Novel HCV vaccine antigens and nanoparticles
新型 HCV 疫苗抗原和纳米颗粒
- 批准号:
10428301 - 财政年份:2022
- 资助金额:
$ 55.32万 - 项目类别:
Novel HCV vaccine antigens and nanoparticles
新型 HCV 疫苗抗原和纳米颗粒
- 批准号:
10557879 - 财政年份:2022
- 资助金额:
$ 55.32万 - 项目类别:
Uncleaved prefusion-optimized trimers on nanoparticles as HIV vaccines
纳米颗粒上未切割的预融合优化三聚体作为 HIV 疫苗
- 批准号:
10307527 - 财政年份:2018
- 资助金额:
$ 55.32万 - 项目类别:
Uncleaved prefusion-optimized trimers on nanoparticles as HIV vaccines
纳米颗粒上未切割的预融合优化三聚体作为 HIV 疫苗
- 批准号:
10062813 - 财政年份:2018
- 资助金额:
$ 55.32万 - 项目类别:
Uncleaved prefusion-optimized trimers on nanoparticles as HIV vaccines
纳米颗粒上未切割的预融合优化三聚体作为 HIV 疫苗
- 批准号:
10524053 - 财政年份:2018
- 资助金额:
$ 55.32万 - 项目类别:
Rational design and B cell responses of HIV epitope vaccines
HIV表位疫苗的合理设计和B细胞反应
- 批准号:
9270983 - 财政年份:2016
- 资助金额:
$ 55.32万 - 项目类别:
Rational design and B cell responses of HIV epitope vaccines
HIV表位疫苗的合理设计和B细胞反应
- 批准号:
10056970 - 财政年份:2016
- 资助金额:
$ 55.32万 - 项目类别:
Novel HCV vaccine antigens targeting conserved neutralizing epitopes
针对保守中和表位的新型 HCV 疫苗抗原
- 批准号:
9096641 - 财政年份:2016
- 资助金额:
$ 55.32万 - 项目类别:
Structure-based immunogen design for hepatitis C virus
基于结构的丙型肝炎病毒免疫原设计
- 批准号:
9091424 - 财政年份:2015
- 资助金额:
$ 55.32万 - 项目类别:
Novel HCV vaccine antigens targeting conserved neutralizing epitopes
针对保守中和表位的新型 HCV 疫苗抗原
- 批准号:
9903198 - 财政年份:
- 资助金额:
$ 55.32万 - 项目类别:
相似海外基金
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
- 批准号:
10506915 - 财政年份:2021
- 资助金额:
$ 55.32万 - 项目类别:
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
- 批准号:
10325006 - 财政年份:2021
- 资助金额:
$ 55.32万 - 项目类别:
SBIR Phase I: A New Class of Immobilized Metal Affinity Chromatography Resins
SBIR 第一阶段:一类新型固定金属亲和色谱树脂
- 批准号:
1746198 - 财政年份:2018
- 资助金额:
$ 55.32万 - 项目类别:
Standard Grant
Marine speciation of nickel using immobilized nickel affinity chromatography
使用固定镍亲和色谱法测定镍的海洋形态
- 批准号:
512537-2017 - 财政年份:2017
- 资助金额:
$ 55.32万 - 项目类别:
University Undergraduate Student Research Awards
I-Corps: Commercialization of Immobilized Metal Affinity Chromatography Resins Based on Nanomaterials
I-Corps:基于纳米材料的固定化金属亲和层析树脂的商业化
- 批准号:
1404605 - 财政年份:2014
- 资助金额:
$ 55.32万 - 项目类别:
Standard Grant
Antibody Purification via Affinity Chromatography that Utilizes the Unconventional Nucleotide Binding Site
利用非常规核苷酸结合位点通过亲和色谱法纯化抗体
- 批准号:
1263713 - 财政年份:2013
- 资助金额:
$ 55.32万 - 项目类别:
Continuing Grant
Development of multivalent DNA network based affinity chromatography diagnostics for isolating circulating tumour cells
开发基于多价 DNA 网络的亲和色谱诊断法,用于分离循环肿瘤细胞
- 批准号:
425749-2012 - 财政年份:2012
- 资助金额:
$ 55.32万 - 项目类别:
Postgraduate Scholarships - Master's
Next-Generation Affinity Chromatography with PEGylated Ligands
使用聚乙二醇化配体的新一代亲和色谱法
- 批准号:
1159886 - 财政年份:2012
- 资助金额:
$ 55.32万 - 项目类别:
Standard Grant
Immobilized zirconium ion affinity chromatography for specific enrichment of phosphoproteins
用于磷蛋白特异性富集的固定化锆离子亲和层析
- 批准号:
19560760 - 财政年份:2007
- 资助金额:
$ 55.32万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Accelerating drug discovery using frontal affinity chromatography/mass spectrometry
使用正面亲和色谱/质谱加速药物发现
- 批准号:
234753-2000 - 财政年份:2003
- 资助金额:
$ 55.32万 - 项目类别:
Collaborative Research and Development Grants